Intravenous, Fc-engineered humanized anti-CD19 IgG1 monoclonal antibody that binds CD19 on B cells to induce antibody-dependent cellular cytotoxicity and phagocytosis and direct apoptosis, depleting tumor B cells.
Fc-engineered humanized anti-CD19 IgG1 monoclonal antibody that binds CD19 on B cells and enhances FcγR-mediated ADCC and ADCP, and can directly induce apoptosis, leading to depletion of malignant CD19+ B cells.
YES
DIRECT
Anti-CD19 IgG1 binds CD19 on B cells; its Fc region engages FcγR on effector cells to trigger ADCC and ADCP, and it can also directly induce apoptosis of CD19+ cells.
Autologous CD141+ dendritic cell vaccine engineered to present the WT1 tumor antigen, aiming to cross-prime and expand WT1-specific CD8+ T-cell cytotoxic responses against pancreatic cancer.
Autologous CD141+ dendritic cells engineered to present WT1 antigen prime and cross-prime T cells by displaying WT1 peptides on MHC I/II, expanding WT1-specific CD8+ cytotoxic and CD4+ helper T-cell responses to target and kill WT1-expressing pancreatic cancer cells.
YES
INDIRECT
Dendritic-cell vaccination primes WT1-specific CD8+ T cells, which recognize WT1 peptides on MHC I of tumor cells and kill them via perforin/granzyme-mediated apoptosis (with CD4+ T-cell help).
Bispecific IgG-like T-cell–engaging antibody (ABBV-383) that binds BCMA on myeloma cells and CD3 on T cells to redirect T-cell cytotoxicity.
Human IgG4 bispecific antibody that binds BCMA on myeloma cells and CD3 on T cells, redirecting cytotoxic T lymphocytes to kill BCMA-expressing tumor cells; incorporates a low-activating CD3 arm to preferentially activate effector T cells and limit cytokine release.
YES
DIRECT
The BCMA×CD3 bispecific antibody binds BCMA on target cells and CD3 on T cells, forming an immune synapse that activates T cells to release perforin/granzymes and kill BCMA-expressing cells.
Bispecific IgG-like T-cell–engaging antibody (ABBV-383) that binds BCMA on myeloma cells and CD3 on T cells to redirect T-cell cytotoxicity.
Human IgG4 bispecific antibody that binds BCMA on myeloma cells and CD3 on T cells, redirecting cytotoxic T lymphocytes to kill BCMA-expressing tumor cells; incorporates a low-activating CD3 arm to preferentially activate effector T cells and limit cytokine release.
NO
INDIRECT
Etentamig binds CD3 on T cells and BCMA on myeloma cells, redirecting T-cell cytotoxicity (perforin/granzyme) to kill BCMA+ tumor cells; CD3+ T cells are activated, not killed.
Anti-SLAMF7 monoclonal antibody that activates NK cells and mediates ADCC against SLAMF7-positive myeloma cells.
Humanized anti-SLAMF7 (CS1) monoclonal antibody that binds SLAMF7 on myeloma and NK cells, activates NK-cell cytotoxicity, and induces Fc-dependent antibody-dependent cellular cytotoxicity (ADCC) against SLAMF7-positive myeloma cells.
YES
DIRECT
Elotuzumab binds SLAMF7 on myeloma cells and its Fc engages FcγRIIIa on NK cells, triggering antibody-dependent cellular cytotoxicity (ADCC) with perforin/granzyme release; it also activates NK cells via SLAMF7 to enhance killing.